Litigation Details for ABBVIE INC. v. QILU PHARMA, INC. (D.N.J. 2024)

ABBVIE INC. v. QILU PHARMA, INC. (D.N.J. 2024)

Docket		Date Filed	2024-06-06
Court	District Court, D. New Jersey	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Zahid Nisar Quraishi
Jury Demand	Defendant	Referred To	Tonianne J. Bongiovanni
Parties	FRESENIUS KABI IPSUM SRL
Patents	7,612,087; 8,471,025; 8,835,455; 8,969,566; 9,284,314; 9,695,122
Attorneys	LIZA M. WALSH
Link to Docket	External link to docket

Details for ABBVIE INC. v. QILU PHARMA, INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-06-06				External link to document

Litigation summary and patent risk analysis for AbbVie Inc. v. Qilu Pharma Inc., No. 3:24-cv-06759 (N.D. California)

Last updated: July 17, 2026

AbbVie’s infringement case against Qilu Pharma (No. 3:24-cv-06759) is filed in 2024 and is structured as an FDA Hatch-Waxman patent dispute tied to a covered ABBVIE product in the Orange Book. The docket caption indicates only the parties and case number; the filing-specific patent list, asserted claims, and the procedural posture are not provided in the prompt, so the analysis below is limited to what is determinable from the case identification.

What does AbbVie Inc. v. Qilu Pharma Inc. (3:24-cv-06759) assert, and what is the litigation posture?

Answer: The case is a federal Hatch-Waxman-type patent infringement action brought by AbbVie against Qilu Pharma in 2024. The specific patents, asserted claims, and whether AbbVie seeks a preliminary injunction are not stated in the prompt.

How to read the case number and what it implies procedurally

• Court and forum: The “3:” prefix corresponds to the federal district court’s docketing scheme for the case.
• Case year: “24” signals filing in 2024.
• Nature of dispute (inferred from parties and typical structure): AbbVie v. Qilu is consistent with a patent infringement challenge associated with an ANDA/BLA submission and Orange Book listed patents, where the brand seeks an injunction and damages.

Key litigation artifacts that usually govern the strategy

In an AbbVie-brand vs. generic defendant case like this, the business-critical inputs are:

• Asserted Orange Book patents and claim numbers
• The defendant’s infringement defenses (non-infringement, invalidity)
• Any section 271(e)(2) trigger tied to FDA approval timing
• Whether AbbVie requested or obtained:
  • Temporary restraining order (TRO) / preliminary injunction
  • Expedited discovery and a claim construction schedule

Which patents protect AbbVie’s product at issue in 3:24-cv-06759, and how strong is AbbVie’s estate?

Answer: The prompt does not include the asserted patent list, expiration dates, or claim sets for 3:24-cv-06759, so the patent estate strength cannot be enumerated.

What you normally map for estate strength (and what’s missing here)

To assess strength in a Hatch-Waxman dispute, you typically produce a table covering:

• Patent numbers asserted
• Filing and priority dates
• Expiration dates including PTA/PTE where applicable
• Type: composition, formulation, method-of-use, manufacturing method, polymorph, crystalline forms, salt forms
• Claim breadth indicators: independent claim count, dependent claim coverage, and whether courts previously construed key terms

Litigation-relevant strength factors that drive outcomes

• Claim construction risk: narrow language can defeat generic entry even if other patents are invalid.
• Obviousness/anticipation posture: the defendant’s invalidity theory can dominate early motion practice.
• Design-around space: if asserted claims cover a single crystalline form or process step, the generic can often avoid infringement.

How does Qilu Pharma’s FDA entry strategy create Paragraph IV risk in AbbVie v. Qilu (3:24-cv-06759)?

Answer: Qilu’s inclusion as the defendant implies an FDA submission and associated Orange Book certifications that trigger infringement jurisdiction under 35 U.S.C. §271(e)(2), but the prompt does not provide the certification type (Paragraph IV vs. other) or the product’s FDA pathway.

What the Paragraph IV record typically controls

Business-critical facts normally found in the complaint and associated ANDA/BLA record:

• Whether Qilu filed Paragraph IV certifications to one or more AbbVie-listed patents
• The triggered patent(s) and the “to” vs. “from” which the dispute is tied
• The proposed drug characteristics:
  • strength
  • dosage form
  • route of administration
  • active ingredient(s) and whether it is a salt, polymorph, or specific formulation variant

What damages and remedies usually follow

If infringement is found, AbbVie typically targets:

• Injunction against launch during remaining exclusivity/patent life
• Reasonable royalty or damages tied to the hypothetical “but for” launch market entry, depending on statutory posture and trial posture

Is AbbVie seeking an injunction, and what are the timeline implications for generic entry?

Answer: The prompt provides no relief request, hearing schedule, or injunction posture. In Hatch-Waxman cases, these are determined by the pleadings and the court’s case management order.

What to look for in the docket (high value items)

• Motion to expedite scheduling
• Claim construction dates
• Daubert or expert schedules (invalidity and infringement)
• Trial date and any stay pending settlement

What typically drives the launch window

• If AbbVie obtains an injunction, Qilu’s launch is barred until the order is lifted or the asserted patents are invalidated.
• If no injunction issues, launch may still be stayed by:
  • procedural posture,
  • later court orders,
  • or a settlement agreement.

What generic entry risks exist for Qilu in 2024-2026, given typical Hatch-Waxman outcomes?

Answer: The prompt contains no ANDA approval date, no expected launch date, and no settlement terms, so launch risk must be treated as undefined from the information provided.

Typical scenario trees in cases like this

• AbbVie wins on at least one asserted patent: entry is delayed or blocked.
• AbbVie loses all asserted patents: generic entry can proceed if FDA approves.
• Partial win: only certain strengths or formulations may be blocked, depending on claim scope and product design.
• Settlement: often creates a branded “at-risk” timeline, with non-launch until a date and/or specified launch design requirements.

How does the case compare with other AbbVie vs. Qilu patent disputes?

Answer: No comparable cases or earlier dockets are provided in the prompt, so cross-case comparison cannot be accurately produced.

What a valid comparison requires

To compare estates and outcomes, you would need:

• prior litigation by AbbVie against Qilu
• the same active ingredient or same drug product family
• the same or different asserted patent families
• consistent ANDA pathway and strength/dosage overlap

What Orange Book status should be expected for ABBVIE at issue in 3:24-cv-06759?

Answer: The prompt does not state which AbbVie product is at issue. Orange Book status depends on the specific NDA/Orange Book record (drug, label, and patent list).

Orange Book fields used in litigation planning

• Orange Book listed patents and patent expiration
• Patent type codes (if used in listing)
• Patent expiration and delisting events
• Remaining exclusivity (NCE, pediatric, orphan, data exclusivity) independent of patent term

Key procedural and business takeaways from the docket ID (what can be stated, and what cannot)

Answer: From the prompt, the case is identified as AbbVie Inc. v. Qilu Pharma Inc., No. 3:24-cv-06759, filed in 2024 in federal court. The specific asserted patents, claim numbers, and schedule are not provided, so no patent-level win/loss probabilities can be calculated.

---

Key Takeaways

• Case ID: AbbVie Inc. v. Qilu Pharma Inc., No. 3:24-cv-06759, filed in 2024.
• Type of dispute: Consistent with Hatch-Waxman patent infringement litigation tied to FDA submission and Orange Book listed patents.
• Patent-level analysis not computable from provided data: No asserted patent list, expiration dates, or claim construction outcomes are included in the prompt, so strength and risk conclusions cannot be made on an estate-by-estate basis.
• Launch timing cannot be quantified: injunction/scheduling/settlement details are not present.

---

FAQs

1. What court likely hears AbbVie v. Qilu Pharma No. 3:24-cv-06759?
   Federal district court indicated by the docket number; the prompt does not specify the venue in text.

2. Is 3:24-cv-06759 a Paragraph IV infringement case?
   The defendant’s profile is consistent with Hatch-Waxman disputes, but the prompt does not state the certification type.

3. Do settlements commonly include “carve-outs” for specific strengths in AbbVie generic litigation?
   Such terms are common in settlements generally, but the prompt provides no settlement record for this case.

4. Can claim construction determine the entire outcome in AbbVie vs. Qilu-type disputes?
   Yes, claim construction often governs infringement and validity analysis, but the prompt provides no claim construction record for this docket.

5. What are the main business levers after filing for a brand in 2024 Hatch-Waxman cases?
   Scheduling for Markman, expedited motions on infringement/invalidity, and negotiating settlement before trial, none of which are described in the prompt for this specific matter.

---

References

No sources were provided in the prompt, and no external case docket content was included to cite.